Objective: The primary objective of the present study was to assess the effect of levodopa-carbidopa intestinal gel (LCIG) on the QoL of patients with advanced Parkinson’s disease (APD) under routine clinical practice.

Background: One of the main purposes of any symptomatic treatment is to improve patients’ quality of life (QoL).

Methods: A prospective observational multicenter study in Spain (20 centers) whose primary objective was to assess the QoL using the PDQ-39 questionnaire (baseline and at 6 months ± 15 days). Changes on the PDQ-39 total score and in its 8 domains were analyzed. Statistical calculation was done by ITT.

Results: 62 patients (age 68.02 ± 7.43 years; 37 males) with years of diagnosis of 12.57 ± 5.97 years were included. In the OFF time, the median H&Y stage was 3 and the Schwab & England score was 30.66 ± 18.52. Fifty-two patients (84%) completed follow-up. The patients’ QoL changed from a baseline score of 46.75 ± 13.59 to 33.94 ± 16.91 after 6 months (p <0.0001). The improvement was statistically significant in all PDQ-39 domains except for "Social support".

Conclusions: The administration of LCIG improves the QoL of patients with APD after 6 months of treatment under routine clinical practice conditions.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/study-on-patient-and-caregiver-reported-symptoms-and-outcomes-with-levodopa-carbidopa-intestinal-gel-for-the-treatment-of-advanced-parkinsons-disease-adequa-study/